Evidence map›Paper›PMID 31678721›Full record

ReviewRedox biology2020

New potential biomarker for stratification of patients for pharmacological vitamin C in adjuvant settings of cancer therapy.

Rumiana Bakalova, Zhivko Zhelev, Thomas Miller, Ichio Aoki, Tatsuya Higashi

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Redox biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. High-dose vitamin C as a metabolic treatment of cancer: a new dimension in the era of adjuvant and intensive therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Antioxidant Therapy in Cancer: Rationale and Progress.Antioxidants (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Frontiers in oncology · 2022
    Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Rumiana BakalovaDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan; Group of Quantum-state Controlled MRI, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan. Electronic address: bakalova.rumiana@qst.go.jp.
Zhivko ZhelevInstitute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Sofia, Bulgaria; Medical Faculty, Trakia University, Stara Zagora, Bulgaria.
Thomas MillerIC-MedTech Co., San Diego, CA, USA.
Ichio AokiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan; Group of Quantum-state Controlled MRI, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), Chiba, Japan.
National Institutes for Quantum and Radiological Science and Technology · JPTrakia University · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our graphical review expands the analysis of cancer vulnerabilities for high dose vitamin C, based on several facts, illustrating the cytotoxic potential of the ascorbate free radical (AFR) via impairment of mitochondrial respiration and the mechanisms of its elimination in mammals by the membrane-bound NADH:cytochrome b5 oxidoreductase 3 (Cyb5R3). We propose that vitamin C can function in "protective mode" or "destructive mode" affecting cellular homeostasis, depending on the intracellular "steady-state" concentration of AFR and differential expression/activity of Cyb5R3 in cancerous and normal cells. Thus, a specific anti-cancer effect can be achieved at high doses of vitamin C therapy. The review is intended for a wide audience of readers - from students to specialists in the field.

Indexed as

Ascorbic AcidBiomarkers, TumorChemotherapy, AdjuvantCytochrome-B(5) ReductaseFree RadicalsHomeostasisHumansNeoplasmsAscorbic AcidBiomarkers, TumorCYB5R3 protein, humanCytochrome-B(5) ReductaseFree RadicalsAscorbate free radicalCancerMitochondriaNADH:Cytochrome b5 oxidoreductase 3Redox signaling

Identifiers

PMID31678721
PMCPMC6920102
OpenAlexW2981917922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.